{
    "clinical_study": {
        "@rank": "154796", 
        "arm_group": [
            {
                "arm_group_label": "Stage 1 Cohort 1", 
                "arm_group_type": "Other", 
                "description": "Vehicle administered to study eye and Sham administered to non-study eye on Day 1"
            }, 
            {
                "arm_group_label": "Stage 1 Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Cyclosporine New Ophthalmic Formulation Dose A administered to study eye and Vehicle administered to non-study eye on Day 1"
            }, 
            {
                "arm_group_label": "Stage 1 Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Cyclosporine New Ophthalmic Formulation Dose B administered to study eye and Vehicle administered to non-study eye on Day 1"
            }, 
            {
                "arm_group_label": "Stage 1 Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1"
            }, 
            {
                "arm_group_label": "Stage 2 Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Cyclosporine New Ophthalmic Formulation (dose to be determined from Stage 1) administered to study eye and Sham administered to non-study eye on Day 1. Both eyes (study eye and non-study eye) will be treated with Cyclosporine New Ophthalmic Formulation beginning at Week 12."
            }, 
            {
                "arm_group_label": "Stage 2 Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Cyclosporine New Ophthalmic Formulation (dose to be determined from Stage 1) administered to study eye and Sham administered to non-study eye on Day 1. Both eyes (study eye and non-study eye) will be treated with Cyclosporine New Ophthalmic Formulation beginning at Week 12."
            }, 
            {
                "arm_group_label": "Stage 2 Group 3", 
                "arm_group_type": "Experimental", 
                "description": "Cyclosporine New Ophthalmic Formulation (dose to be determined from Stage 1) administered to study eye and Sham administered to non-study eye on Day 1. Both eyes (study eye and non-study eye) will be treated with Cyclosporine New Ophthalmic Formulation beginning at Week 12."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate a new ophthalmic formulation of cyclosporine (Restasis\u00ae X) in\n      patients with moderate to severe dry eye disease in two stages.  Up to 3 doses will be\n      studied in Stage 2 based on results from Stage 1.  No patients participating in Stage 1 will\n      participate in Stage 2 of this study."
        }, 
        "brief_title": "Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis\u00ae X) in Patients With Dry Eye Disease", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Dry Eye Syndromes", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Moderate to severe dry eye disease in both eyes\n\n          -  Best-corrected visual acuity (BCVA) of 20/100 or better in each eye\n\n        Exclusion Criteria:\n\n          -  Use of any cyclosporine preparations within 3 months\n\n          -  Use of topical medications, other than artificial tears, in the eyes within 1 month\n\n          -  Use of contact lenses in either eye within 1 month\n\n          -  Stage 2 only:  Participation in Stage 1 of this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013791", 
            "org_study_id": "192371-024"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Stage 1 Cohort 1", 
                    "Stage 1 Cohort 2", 
                    "Stage 1 Cohort 3", 
                    "Stage 1 Cohort 4"
                ], 
                "description": "Vehicle of cyclosporine administered as per protocol on Day 1", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Stage 1 Cohort 1", 
                    "Stage 2 Group 1", 
                    "Stage 2 Group 2", 
                    "Stage 2 Group 3"
                ], 
                "description": "Sham administered to non-study eye as per protocol on Day 1", 
                "intervention_name": "Sham", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Stage 1 Cohort 2", 
                    "Stage 1 Cohort 3", 
                    "Stage 1 Cohort 4", 
                    "Stage 2 Group 1", 
                    "Stage 2 Group 2", 
                    "Stage 2 Group 3"
                ], 
                "description": "Cyclosporine New Ophthalmic Formulation administered as per protocol", 
                "intervention_name": "Cyclosporine New Ophthalmic Formulation", 
                "intervention_type": "Drug", 
                "other_name": "Restasis\u00ae X"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "More Information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Artesia", 
                    "country": "United States", 
                    "state": "California"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "7", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Corneal Staining Score Using a 6-Point Scale", 
            "safety_issue": "No", 
            "time_frame": "24 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013791"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}